SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares (GLD) is experiencing a sharp, volatile sell-off as investors rapidly unwind positions, causing the ETF to trade more like a high-beta tech stock than a traditional safe haven. The community is actively debating whether this is a forced liquidity event driven by margin calls and profit-taking or a fundamental shift in gold's status amid rising yields, a strengthening dollar, and geopolitical instability.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

The iShares Silver Trust is experiencing intense selling pressure and high volatility, with the community actively debating whether the current drop represents a generational buying opportunity or a deeper correction toward support levels near 50-60 dollars. Traders are largely attributing the decline to a broader liquidity crisis, rising yields, and a stronger dollar, while long-term investors emphasize physical silver demand and industrial shortages as reasons to hold despite the current market bloodbath.

AleAnna, Inc. operates as a technology-driven energy company, which engages in supplying low-carbon natural gas and renewable natural gas to Italy. The company was founded in 2007 and is headquartered in Dallas, TX.

AleAnna Inc. - Ordinary Shares - Class A

AleAnna Inc. is surging due to a massive volume spike driven by geopolitical tensions in the Middle East, specifically reports of supply disruptions at Qatar's LNG facilities that have heightened concerns over energy security in Europe. The community is actively discussing the stock's potential as a multi-day runner, with many traders drawing parallels to past energy sector volatility while debating the impact of the ongoing conflict on natural gas supply.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Dallas, TX.

United States Antimony Corp.

United States Antimony Corp is currently trending as investors monitor ongoing supply chain concerns and the company's role as a critical, U.S.-based supplier of antimony for defense and high-tech applications. The community is actively discussing the impact of geopolitical tensions, government contract backlogs, and recent earnings, with many focusing on the potential for institutional accumulation and the long-term strategic necessity of domestic mineral production.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is experiencing significant market attention as investors weigh robust vehicle delivery projections and positive operational developments against persistent volatility, driven in part by ongoing discussions regarding potential share dilution and broader macroeconomic headwinds. The community is actively debating the company's long-term potential, with bulls highlighting the expansion of its battery swap infrastructure and in-house chip technology as key competitive advantages, while skeptics remain cautious due to historical stock price performance and the impact of frequent trading of options.

WeShop Holdings Ltd. engages in providing a shoppable social network. It offers shopping in fashion and accessories, health and beauty, home and DIY, food and drink, travel and holidays, tech and electronics, and other popular categories. It includes a library of shoppable product reviews from a digital online shopping mall on mobile devices. The company was founded by John Garner on September 21, 2012 and is headquartered in Jersey, the United Kingdom.

WeShop Holdings Ltd - Ordinary Shares - Class A

WeShop Holdings Limited

WeShop Holdings is trending as investors react to the company's recent direct listing and community-owned commerce model, which has fueled intense retail speculation and volatility. Community discussion is sharply divided, with bulls highlighting potential growth from retail partnerships and aggressive expansion efforts, while skeptics point to the company's thin float and concerns over its long-term financial viability.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is currently in the spotlight as investors grapple with the fallout from federal indictments against former employees and a co-founder for a sophisticated chip-smuggling scheme to China. While some community members are bracing for further volatility and potential delisting risks, others argue the sell-off is an overreaction, pointing to the company's status as a victim in the indictment and its strong underlying position in the AI infrastructure market.

Two Harbors Investment Corp. is a real estate investment trust, which invests in finances, and manages agency residential mortgage-backed securities, mortgage servicing rights, and other financial assets. The company was founded on May 21, 2009 and is headquartered in St. Louis Park, MN.

Two Harbors Investment Corp

Two Harbors Investment Corp. is trending due to an unsolicited all-cash acquisition offer of $10.70 per share, prompting an active community debate over whether the bid represents a superior proposal compared to the existing UWM Holdings merger agreement. Investors are closely analyzing the offer against the company's underlying book value and debating the likelihood of a higher counter-offer amid ongoing market volatility.

Coeur Mining, Inc. engages in the well-diversified, growing precious metals producer with a focus on generating sustainable, high-quality cash flow and returns from a balanced, prospective asset base in mining-friendly jurisdictions along with commitment to exploration and expansions. It operates through the following segments: Palmarejo, Rochester, Kensington, Wharf and Silvertip. The Palmarejo segment includes a gold-silver complex. The Rochester segment operates an open pit heap leach silver-gold mine in northwestern Nevada. The Kensington segment relates to an underground gold mine located north of Juneau, Alaska. The Wharf segment focuses on an open pit heap leach gold mine located near Lead, South Dakota. The Silvertip segment silver-zinc-lead exploration located in the state of Sonora in northern Mexico. The company was founded in 1928 and is headquartered in Chicago, IL.

Coeur Mining Inc

Coeur Mining is drawing significant investor attention due to record-breaking quarterly financial performance and the highly anticipated completion of its merger with New Gold. The community is actively debating the stock's potential for a major re-rating, fueled by strong gold and silver production levels and broader optimism across the precious metals sector.

ProShares Trust - ProShares Ultra Silver 2x Shares

ProShares Ultra Silver

ProShares Ultra Silver (AGQ) is facing extreme volatility and a sharp downward slide as investors grapple with massive price swings, liquidations, and heightened anxiety over the sustainability of recent rallies. The community is actively debating whether this is a structural market reset driven by technical manipulation and shifting institutional flows, or a temporary cooling period for a commodity previously inflated by aggressive sentiment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Seth Lederman Purchases 15,000 Shares of Tonix Pharmaceuticals (NASDAQ:TNXP) Stock

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report) CEO Seth Lederman acquired 15,000 shares of the firm's stock in a transaction that occurred on Wednesday, March 18th. The stock was acquired at an average price of $14.89 per share, for a total transaction of $223,350.00. Following...

Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Seth Lederman Acquires 15,000 Shares

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report) CEO Seth Lederman acquired 15,000 shares of Tonix Pharmaceuticals stock in a transaction dated Wednesday, March 18th. The shares were purchased at an average price of $14.89 per share, with a total value of $223,350.00. Following...

Noble Financial Has Optimistic Outlook of TNXP Q1 Earnings

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) - Stock analysts at Noble Financial upped their Q1 2026 EPS estimates for shares of Tonix Pharmaceuticals in a research note issued on...

<ul class="summary-bullets"><li>CEO Seth Lederman said early trends show favorable prescriber uptake and repeat utilization.</li><li>Investors are also watching TNX-4800, with the company planning FDA talks on Phase 2/3 development and potential studies beginning in 2027-2028.</li><li>Tonix posted a net loss of $46.9 million in Q4, compared with a net loss of $22.1 million a year ago.</li></ul><p>Shares of Tonix Pharmaceuticals (TNXP) rose over 1% in premarket trading on Friday as investors cheered early prescription traction for its fibromyalgia drug Tonmya and growing interest in its Lyme disease prevention program, despite a wider quarterly loss.</p><p><a href="https://stocktwits.com/symbol/TNXP">TNXP stock</a> is headed for its seventh straight week of losses and has declined 0.3% so far this week.</p><h2 class="st-heading-2"><strong>Tonmya Launch Gains Early Prescriber Traction</strong></h2><p>Tonix said Tonmya, approved by the U.S. Food and Drug Administration (FDA) in August 2025 for fibromyalgia in adults, is showing early adoption after its Nov.17, 2025, commercial launch. The therapy is the first new prescription medicine approved for fibromyalgia in more than 15 years.</p><p>Through Feb.27, more than 1,500 healthcare providers had prescribed Tonmya, about 2,500 patients had initiated treatment and cumulative prescriptions reached nearly 4,200, including bridge prescriptions provided through the company’s specialty pharmacy channel.</p><p>“Early prescription trends reflect favorable prescriber uptake and repeat utilization consistent with our internal launch expectations,” CEO Seth Lederman said in a statement. Tonix has established distribution through wholesalers, specialty pharmacies, and patient support programs, including copay assistance and prior authorization services.</p><p>Speaking at the Life Sciences Virtual Investor Forum on Wednesday, Lederman said early anecdotal feedback suggests patients are reporting positive results and that prescribing is occurring across multiple specialties, including rheumatology, primary care, pain management and neurology.</p><h2 class="st-heading-2"><strong>Lyme Disease Prevention Drug In Focus</strong></h2><p>Investors have also been paying attention to TNX-4800, a long-acting monoclonal antibody for the seasonal prevention of Lyme disease, an area with no FDA-approved vaccines or prophylactic treatments currently available.</p><p>Tonix plans to meet with the FDA this year to discuss Phase 2/3 development options, including a field study and a controlled human infection model study. The company expects investigational products to be available in early 2027, with a U.S. field study potentially beginning in 2027 and a human challenge study planned for 2028.</p><h2 class="st-heading-2"><strong>TNXP Q4 Review</strong></h2><p>Tonix reported fourth-quarter (Q4) revenue of about $534 million, significantly up from $2.6 million a year earlier. However, the company posted a net loss of $46.9 million, or $3.98 per share, compared with a net loss of $22.1 million, or $9.77 per share, in the same period a year ago.</p><p>Tonix ended 2025 with $207.6 million in cash and cash equivalents, which will fund operations into the first quarter of 2027.</p><h2 class="st-heading-2"><strong>How Did Stocktwits Users React?</strong></h2><p>On Stocktwits, retail sentiment for TNXP was ‘extremely bullish’ amid ‘extremely high’ message volume.</p><figure class="image"><img src="https://news.stocktwits-cdn.com/tnxp_ss_png_63ee8c6e92.webp" alt="tnxp ss.png" width="969" height="141"><figcaption>TNXP sentiment and message volume as of March 13 | Source: Stocktwits</figcaption></figure><p>One user&nbsp;<a href="https://stocktwits.com/curiousturtle2000/message/647416946">called</a> Tonix’s latest&nbsp;earnings report “very encouraging.”</p><p><stembedurl>https://stocktwits.com/curiousturtle2000/message/647416946</stembedurl></p><p>Another user&nbsp;<a href="https://stocktwits.com/StockJayC/message/647411678">said</a>, “$20m-$25m cash burn = 2 years continuing at the current burn with no change to operations or factoring revenue increases,” adding that they expect the stock to rise over $60 by June.&nbsp;</p><p><stembedurl>https://stocktwits.com/StockJayC/message/647411678</stembedurl></p><p>TNXP stock has declined 14% so far this year.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Tonix Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

TNXP Stock Rises Premarket: Investors Cheer Early Traction For Fibromyalgia Drug Despite Weak Q4 Print

Tonmya launch gained early uptake, with over 1,500 healthcare providers prescribing the drug until Feb.27.

Equity

Tonix Pharmaceuticals (NASDAQ:TNXP) Releases Earnings Results, Misses Estimates By $0.99 EPS

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) released its earnings results on Thursday. The company reported ($4.15) EPS for the quarter, missing the consensus estimate of ($3.16) by...

Tonix Pharmaceuticals (TNXP) Expected to Announce Earnings on Tuesday

Tonix Pharmaceuticals (NASDAQ:TNXP) will be releasing its Q4 2025 earnings before the market opens on Tuesday, March 17. (View Earnings Report at...

Tonix Pharmaceuticals (NASDAQ:TNXP) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded Tonix Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday...

Tonix Pharmaceuticals (NASDAQ:TNXP) Cut to "Sell" at Wall Street Zen

Wall Street Zen downgraded Tonix Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday...

<ul class="summary-bullets"><li>Tonix intends to advance TNX-4800 with the goal of submitting an application to the FDA seeking approval to market it.</li><li>The company licensed TNX-4800 from its developers at UMass Chan Medical School in September.</li><li>There are currently no FDA-approved vaccines or preventive medicines to protect against Lyme disease.</li></ul><p>Tonix Pharmaceuticals Holding Corp. (TNXP) announced on Monday that it intends to meet with the U.S. Food and Drug Administration in 2026 to discuss the development of its experimental drug in the treatment of Lyme disease.</p><p>The company licensed TNX-4800 from its developers at UMass Chan Medical School in September. It is being developed for annual seasonal use, as one subcutaneous administration in the spring to protect against Lyme disease through fall, or the entire tick season in the U.S., without relying on the recipient’s immune system to generate antibodies.</p><h2 class="st-heading-2">What Is Lyme Disease?</h2><p>Lyme disease is a bacterial infection caused by the bacterium Borrelia burgdorferi and spread by infected blacklegged ticks. It causes symptoms such as a bull's-eye rash, fever, fatigue, and headaches, and, if untreated, can spread to joints, heart, and brain.</p><p>There are currently no FDA-approved vaccines or preventive medicines to protect against Lyme disease. According to Tonix, it is the most common vector-borne infection in the United States, and its incidence is climbing each year.</p><h2 class="st-heading-2">Tonix Eyes Advancing The Drug</h2><p>Tonix intends to advance TNX-4800 with the goal of submitting an application to the FDA seeking approval to market it.</p><p>“We believe a controlled human infection model (CHIM)3-5 study using Borrelia-infected ticks that mimics natural infection would be a potential path to demonstrating TNX-4800 efficacy for approval,” <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tonixpharma.com/news-events/press-releases/detail/1606/tonix-pharmaceuticals-announces-program-updates-on-phase">said</a> CEO Seth Lederman. He added that the firm expects to have the investigational product ready for clinical trials by early 2027.</p><h2 class="st-heading-2">Registered Direct Offering</h2><p>Separately, the company also announced the pricing of a $20.0 million registered direct offering on Monday<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tonixpharma.com/news-events/press-releases/detail/1607/tonix-pharmaceuticals-announces-pricing-of-20-0-million"> at about</a> $16.26 per share/warrant. &nbsp;The firm intends to use the net proceeds from the offering to fund the commercialization of its marketed products, the development of its product pipeline, and general working capital and corporate purposes.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around TNXP stayed within the ‘bearish’ territory while message volume stayed at ‘low’ levels.</p><p>A Stocktwits user sounded optimistic about the stock.</p><p><stembedurl>https://www.stocktwits.com/ZenofWealth/message/640294827</stembedurl></p><p><a href="https://stocktwits.com/symbol/TNXP">TNXP stock</a> is down 51% this year and by about 55% over the past 12 months.&nbsp;</p><p>Also See: <a href="https://stocktwits.com/news-articles/markets/equity/nasa-administrator-jared-isaacman-sees-us-return-to-moon-before-trump-presidential-term-expiry/cLeCD4iREDB">NASA Administrator Jared Isaacman Sees US Return To Moon Before Trump’s Presidential Term Expiry</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

Tonix Pharmaceuticals To Meet With FDA In 2026 To Advance Experimental Lyme Disease Prevention Drug

The company also announced the pricing of a $20 million registered direct offering. 

Noble Financial Has Positive Outlook of TNXP FY2025 Earnings

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) - Investment analysts at Noble Financial raised their FY2025 earnings per share estimates for shares of Tonix Pharmaceuticals in a...

$TNXP Q4 &#39;25 Earnings Results &amp; Recap

Tonix Pharmaceuticals Holding Corp. reported net product revenue of $13.1M in 2025, an increase from $10.1M in 2024, with a net loss of $124M in 2025, an improvement from $130M in 2024.

Stocktwits

Tonix Pharmaceuticals Holding Corp

 Q4 '25 Earnings Results & Recap

Tonix Pharmaceuticals Holding Corp. reported net product revenue of $13.1M in 2025, an increase from $10.1M in 2024, with a net loss of $124M in 2025, an improvement from $130M in 2024.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.

Current Price	$15.00
Prev Close	$15.77
Open	$15.74
Dividend Yield	0.00%
50-Day Moving Average	$15.55
Beta	1.21
Avg. Volume	333,299.34
PE Ratio	-1.05

52-Week High	$69.97
52-Week Low	$13.07
Market Capitalization	$201.08M
EPS (Annual)	-$14.57
Price to Book	0.78
Revenue Per Employee	$92,302.82

TNXP
Tonix Pharmaceuticals Holding Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TNXP News

TNXPTonix Pharmaceuticals Holding Corp